Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records
Reason given: No patients consented to enrollment
Key facts
- Where
- New Haven, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- Yale New Haven HospitalNew Haven, United StatesNo longer taking part
Trial details
- Who runs it
- Yale University
- Trial code
- NCT04569903
- Record updated
- 18 September 2025
- Original description
The primary objective of this study is to evaluate the diagnostic performance of an algorithm in identifying patients with ATTR amyloidosis.Read full original descriptionShow less
Evaluation of a Claims-based Algorithm for the Identification of ATTR Amyloidosis in Medical Records
The primary objective of this study is to evaluate the diagnostic performance of an algorithm in identifying patients with ATTR amyloidosis.
Inclusion: Identified by the ATTR diagnostic algorithm and matched by Yale's list of potential subjects defined as:; subjects within the claims dataset that are predicted to be at risk of having ATTR who are also being managed within YNHHS; patients who need to be contacted and offered additional clinical evaluation to determine whether they have a diagnosis of ATTR (non-hereditary or Hereditary ATTR amyloidosis).
Exclusion: Patients who have opted out of research in the Epic system will be excluded entirely from the study; Patients who are pregnant or who may become pregnant.